Abstract
Dyslipidemias including familial hypercholesterolemia and elevated lipoprotein (a) are not uncommon in young women who may desire pregnancy. In all women, abnormal lipid metabolism has been linked to adverse outcomes during pregnancy, including hypertensive disease of pregnancy, gestational diabetes mellitus, and preterm birth. Optimal management of dyslipidemias in pregnant women remains undefined, as statins are contraindicated in this group. Recent literature questions this traditional avoidance of statins, however, as well as explores their potential benefit in pre-eclampsia specifically. In this review, the arsenal of nutrition, bile acid resins, omega-3 fatty acids, and low-density lipoprotein cholesterol apheresis is explored, as are newer therapies like mipomersen and proprotein convertase subtilisin/kexin type 9 inhibitors, for the management of dyslipidemias during pregnancy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
